Derrick Haslem, MD
Hematology & Oncology · St George, UTNPI 1730389701
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,150 of the $3,265 with a category attached, or 96.5%. Myriad Genetic Laboratories, Inc. accounts for 96.5% of it on its own, with 6 other manufacturers making up the rest. 2024 is the largest year on record at $3,150, more than ten times the $30 reported in 2019. That places this record below the midpoint for hematology & oncology clinicians in UT, where the typical reported total is $2,350.
Across 11 payments — averaging $296.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Myriad Genetic Laboratories, Inc.$3K
- Merck$40
- Genentech USA, Inc.$19
- E.r. Squibb & Sons, L.L.C.$17
- Bayer$17
- Gilead$12
- plus $10 from 1 others
Across 33 payments — averaging $10,399 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Roche Products Limited$258K
- Myriad Genetic Laboratories, Inc.$73K
- Astrazeneca UK Limited$11K
- Hoffmann-la Roche Limited$800
What the payments were for
- Consulting fees$3,15096%
- Food & beverage$361%
- Education$792%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Myriad Genetic Laboratories, Inc. | 4 | $3,150 |
| Merck | 2 | $40 |
| Genentech USA, Inc. | 1 | $19 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Bayer | 1 | $17 |
| Gilead | 1 | $12 |
| Clovis Oncology, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- myRisk$3,150
How this compares
$3,265 in reported general payments places this provider in the 50th percentile of 77 hematology & oncology providers in Utah.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Abiraterone Acetate | 57 | $6,184 |
| Anastrozole | 31 | $608 |
| ValacyclovirValacyclovir Hcl | 19 | $550 |
| Prochlorperazine Maleate | 39 | $454 |
| Prednisone | 45 | $424 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 11 | $222 |
| Ondansetron OdtOndansetron | 18 | $218 |
| Dexamethasone | 15 | $206 |
| Ondansetron Hcl | 18 | $190 |
| Levothyroxine Sodium | 11 | $50 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in St George
- Joseph TeSt George$29K
- Zachary ReeseSt George$648
- Douglas SborovSalt Lake City$473K
- Belisario ArangoOgden$374K
- Mark LewisMurray$319K
- Daniel CourielSalt Lake City$229K
- Shiven PatelSalt Lake City$223K
- Neeraj AgarwalSalt Lake City$159K
- Terence RhodesCedar City$147K
- Benjamin MaughanSalt Lake City$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.